Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil

por Trivedi, Ashit, Oberoi, Rajneet K., Jafarinasabian, Pegah, Zhang, Hanze, Flach, Stephen, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward
Publicado 2021

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

por Cadieux, Benoit, Coleman, Robert, Jafarinasabian, Pegah, Lipton, Allan, Orlowski, Robert Z., Saad, Fred, Scagliotti, Giorgio V., Shimizu, Kazuyuki, Stopeck, Alison
Publicado 2022

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects

por Trivedi, Ashit, Sohn, Winnie, Hsu, Cheng‐Pang, Jafarinasabian, Pegah, Zhang, Hanze, Hutton, Shauna, Flach, Stephen, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward
Publicado 2021

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐b...

por Trivedi, Ashit, Sohn, Winnie, Kulkarni, Priyanka, Jafarinasabian, Pegah, Zhang, Hanze, Spring, Marintan, Flach, Stephen, Abbasi, Siddique, Wahlstrom, Jan, Lee, Edward, Dutta, Sandeep
Publicado 2021